← Back to Screener
IGC Pharma, Inc. (IGC)
Price$0.32
Favorite Metrics
Price vs S&P 500 (26W)-28.51%
Price vs S&P 500 (4W)10.33%
Market Capitalization$31.61M
All Metrics
Book Value / Share (Quarterly)$0.08
P/TBV (Annual)11.25x
Revenue Growth (3Y)-1.52%
Cash Flow / Share (Quarterly)$-0.07
Price vs S&P 500 (YTD)11.07%
Gross Margin (TTM)37.61%
Net Profit Margin (TTM)-445.62%
EPS (TTM)$-0.06
10-Day Avg Trading Volume0.47M
EPS Excl Extra (TTM)$-0.06
Revenue Growth (5Y)-0.70%
EPS (Annual)$-0.05
ROI (Annual)-54.86%
Gross Margin (Annual)34.18%
Net Profit Margin (5Y Avg)-1404.75%
Cash / Share (Quarterly)$0.01
Revenue Growth QoQ (YoY)36.19%
ROA (Last FY)-42.69%
Revenue Growth TTM (YoY)-2.99%
EBITD / Share (TTM)$-0.06
ROE (5Y Avg)-97.20%
Operating Margin (TTM)-763.72%
Cash Flow / Share (Annual)$-0.06
P/B Ratio4.26x
P/B Ratio (Quarterly)3.52x
Net Income / Employee (Annual)$-0
EV / Revenue (TTM)25.73x
Net Interest Coverage (TTM)-58.67x
ROA (TTM)-59.13%
EV / EBITDA (TTM)9.70x
EPS Incl Extra (Annual)$-0.05
Current Ratio (Annual)0.83x
Quick Ratio (Quarterly)0.47x
3-Month Avg Trading Volume0.51M
52-Week Price Return13.72%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$0.02
P/S Ratio (Annual)36.38x
Asset Turnover (Annual)0.09x
52-Week High$0.50
Operating Margin (5Y Avg)-1519.14%
EPS Excl Extra (Annual)$-0.05
CapEx CAGR (5Y)-16.30%
Tangible BV CAGR (5Y)-40.97%
26-Week Price Return-24.53%
Quick Ratio (Annual)0.47x
13-Week Price Return6.70%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)0.83x
Enterprise Value$30.849
Revenue / Share Growth (5Y)-14.46%
Asset Turnover (TTM)0.13x
Book Value / Share Growth (5Y)-35.25%
Revenue / Employee (Annual)$0
Inventory Turnover (Annual)0.45x
Pretax Margin (Annual)-477.10%
Cash / Share (Annual)$0.01
3-Month Return Std Dev48.78%
Gross Margin (5Y Avg)46.65%
Net Income / Employee (TTM)$-0
ROE (Last FY)-55.85%
Net Interest Coverage (Annual)-7.57x
EPS Basic Excl Extra (Annual)$-0.05
P/FCF (TTM)117.09x
Receivables Turnover (TTM)39.31x
Total Debt / Equity (Quarterly)0.02x
EPS Incl Extra (TTM)$-0.06
Receivables Turnover (Annual)34.82x
ROI (TTM)-75.08%
P/S Ratio (TTM)26.37x
Pretax Margin (5Y Avg)-1404.75%
Revenue / Share (Annual)$0.01
Tangible BV / Share (Annual)$0.02
Price vs S&P 500 (52W)-16.11%
Year-to-Date Return13.72%
5-Day Price Return6.31%
EPS Normalized (Annual)$-0.05
ROA (5Y Avg)-75.67%
Net Profit Margin (Annual)-477.10%
Month-to-Date Return21.67%
Cash Flow / Share (TTM)$-0.19
EBITD / Share (Annual)$-0.04
Operating Margin (Annual)-891.25%
LT Debt / Equity (Annual)0.02x
ROI (5Y Avg)-95.63%
LT Debt / Equity (Quarterly)0.02x
EPS Basic Excl Extra (TTM)$-0.06
P/TBV (Quarterly)11.25x
P/B Ratio (Annual)3.52x
Inventory Turnover (TTM)0.72x
Pretax Margin (TTM)-445.62%
Book Value / Share (Annual)$0.08
Price vs S&P 500 (13W)6.01%
Beta0.47x
Revenue / Share (TTM)$0.01
ROE (TTM)-76.54%
52-Week Low$0.24
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
IGCIGC Pharma, Inc. | 26.37x | -2.99% | 37.61% | — | $0.32 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
About
IGC Pharma develops cannabinoid-based therapeutics for neurological and pain disorders. The company's Alzheimer's disease program includes four investigational candidates (IGC-AD1, IGC-M3, IGC-1C, and TGR-63) that have demonstrated preclinical potential to reduce amyloid plaques and tau tangles. Additional pipeline programs target period cramps, premenstrual syndrome, and chronic pain.